Adline Ghazi, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1609033869
Payments from drug & device makers
Across 399 payments — averaging $3013.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$871K
- Novo Nordisk AS$158K
- Novartis$106K
- Boehringer Ingelheim Pharma GmbH & Co.kg$40K
- Janssen Research & Development, LLC$16K
- Boehringer Ingelheim International GmbH$9K
- plus $2K from 20 others
Across 12 payments — averaging $5317.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$63K
- Novo Nordisk AS$766
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 43 | $871,021 |
| Novo Nordisk AS | 244 | $158,486 |
| Novartis | 6 | $106,472 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $40,062 |
| Janssen Research & Development, LLC | 8 | $15,752 |
| Boehringer Ingelheim International GmbH | 10 | $8,500 |
| Lilly USA, LLC | 28 | $554 |
| Novo Nordisk | 11 | $240 |
| Boehringer Ingelheim | 7 | $198 |
| Corcept Therapeutics | 7 | $163 |
| Radius Health, Inc. | 3 | $141 |
| Dexcom, Inc. | 7 | $140 |
| Tandem Diabetes Care, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Amgen | 1 | $66 |
| Medtronic(2 entities) | 3 | $63 |
| Insulet Corporation | 3 | $44 |
| Abbott | 2 | $43 |
| BETA Bionics, Inc. | 1 | $43 |
| BD | 1 | $39 |
| Embecta Corp. | 1 | $33 |
| Bayer | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| AbbVie | 1 | $17 |
How this compares
$1,202,294 in reported general payments places this provider in the 95th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Washington
- Henry BurchWashington$25.2M
- Sabyasachi SenWashington$1.4M
- Kenneth BurmanWashington$219K
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Michelle MageeWashington$61K
- Abbas MotazediWashington$31K
- Julia PinedaWashington$29K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.